



Published in final edited form as:

Nat Med. 2010 June ; 16(6): 671–677. doi:10.1038/nm.2158.

A genome-wide RNA interference screen reveals an essential CREB3L2/ATF5/MCL1 survival pathway in malignant glioma with therapeutic implications

Zhi Sheng¹, Li Li², Lihua J. Zhu³, Thomas W. Smith⁴, Andrea Demers⁵, Alonzo H. Ross², Richard P. Moser⁵, and Michael R. Green¹

¹Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

²Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

³Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

⁴Department of Pathology and Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

⁵Department of Surgery, Division of Neurosurgery, University of Massachusetts Medical School, Massachusetts Center for Translational Research in Neurosurgical Oncology, Worcester, Massachusetts, USA.

Abstract

Activating transcription factor 5 (ATF5) is highly expressed in malignant glioma and plays an important role in promoting cell survival. Here we perform a genome-wide RNA interference (RNAi) screen to identify transcriptional regulators of *ATF5*. Our results reveal an essential survival pathway in malignant glioma, whereby activation of a RAS/MAPK or PI3K signaling cascade leads to induction of the transcription factor CREB3L2, which directly activates *ATF5* expression. ATF5, in turn, promotes survival by stimulating transcription of MCL1, an anti-apoptotic BCL2 family member. Analysis of human malignant glioma samples indicates that ATF5 expression inversely correlates with disease prognosis. The RAF inhibitor sorafenib suppresses ATF5 expression in glioma stem cells and inhibits malignant glioma growth in cell culture and mouse xenografts. Our results demonstrate that ATF5 plays an essential role in malignant glioma genesis, and reveal that the ATF5-mediated survival pathway described here provides potential therapeutic targets for treatment of malignant glioma.

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence should be addressed to M.R.G. (michael.green@umassmed.edu).

Author Contributions

Z.S. and M.R.G. designed all experiments. Z.S. performed all experiments. Z.S. and M.R.G. prepared the manuscript. L.L. and A.H.R. assisted with intracranial injections. T.W.S., A.D. and R.P.M. helped analyze human malignant gliomas. L.J.Z. performed all statistical analyses.

A hallmark of cancer is uncontrolled cellular proliferation, which can arise as a result of over-expression of genes promoting cell survival or down-regulation of genes inducing cell death¹. Genes that are highly expressed in cancer cells and are essential for their survival are appealing targets for the development of novel cancer therapeutics².

ATF5 (also known as ATFx) is a member of the ATF/camp responsive element-binding (CREB) family of transcription factors, which comprises a large group of basic leucine zipper proteins whose members mediate diverse transcriptional regulatory functions³. ATF5 is an anti-apoptotic factor that plays an important role in promoting survival in a variety of cell types⁴. Increased levels of ATF5 have been observed in primary brain tumors, and ATF5 expression is particularly high in glioblastoma, an aggressive form of malignant glioma⁵. Previous studies have shown that interference with ATF5 function results in glioma cell death in primary tumors but does not affect normal cells surrounding the tumor⁶. The high level of ATF5 in brain tumors, coupled with the absence of ATF5 expression in mature neurons, suggests that ATF5 may be an attractive therapeutic target for the treatment of malignant glioma.

The upstream regulators of ATF5 expression and the downstream effectors that mediate the anti-apoptotic effects of ATF5 remain to be determined. Here we describe a novel genome-wide RNAi negative-selection screening strategy that has enabled us to elucidate a pathway by which ATF5 is expressed and prevents apoptosis. Our results reveal an essential survival pathway in malignant glioma, the inhibition of which has therapeutic implications.

RESULTS

A signaling pathway required for ATF5 expression

To identify factors that regulate *ATF5* transcription, we performed a genome-wide small hairpin RNA (shRNA) screen to isolate genes that, when knocked down, greatly reduce *ATF5* expression. Because loss of ATF5 function would induce apoptosis^{5,7} and prevent the subsequent identification of candidate shRNAs, we developed a negative-selection strategy (Fig. 1a) based on the ability of diphtheria toxin (DT) to kill cells expressing the DT receptor (DTR). Mouse cells lack a functional DTR and are resistant to DT⁸. We generated a mouse malignant glioma GL261 cell line stably expressing the human DTR driven by the mouse *Atf5* promoter (pATF5-DTR). To prevent cell death due to loss of endogenous ATF5, we also engineered the cell line to stably express ATF5 driven by the constitutive cytomegalovirus (CMV) promoter (pCMV-ATF5). The resulting cell line was termed GL261/pATF5-DTR/pCMV-ATF5; as expected, these cells were efficiently killed by addition of DT (Supplementary Fig. 1a).

A mouse shRNA library comprising ~62,400 shRNAs directed against ~28,000 genes⁹ was divided into 10 pools, which were packaged into retrovirus particles and used to stably transduce GL261/pATF5-DTR/pCMV-ATF5 cells. We treated cells with DT, and isolated DT-resistant clones. We identified positive shRNAs by sequence analysis and tested their ability to inhibit endogenous *Atf5* gene expression (Supplementary Fig. 1b). Using this approach, we identified and validated 12 genes that were required for endogenous *Atf5* expression in mouse malignant glioma GL261 cells (Supplementary Table 1).

We elected to focus on three factors: fibroblast growth factor receptor (FGFR) substrate 2 (FRS2), p21 protein-activated kinase 1 (PAK1) and CREB protein 3-like 2 (CREB3L2). FRS2 is a docking protein that binds to receptor tyrosine kinases, such as FGFR or epidermal growth factor receptor (EGFR), and leads to activation of RAS signaling¹⁰; notably, the RAS signaling pathway is frequently activated in malignant gliomas due to aberrant expression of receptor tyrosine kinases including FGFR and EGFR¹¹. PAK1 is a kinase that functions as a positive regulator of mitogen-activated protein kinase (MAPK) signaling^{10,12}. CREB3L2 is a member of the CREB family of transcription factors, which bind to DNA sequences known as cAMP responsive elements (CRE)¹³. CREB3L2 is homologous to CREB3, whose activity and expression is regulated by MAPK signaling¹⁴. We therefore hypothesized that FRS2, PAK1 and CREB3L2 comprise a signaling pathway that culminates in increased *Atf5* expression. To test this hypothesis, we first confirmed that FRS2, PAK1 and CREB3L2 were required for *Atf5* expression. We designed small interfering RNAs (siRNAs) against FRS2, PAK1 and CREB3L2 whose sequences were unrelated to the shRNAs isolated in the primary screen; siRNA-mediated knockdown of FRS2, PAK1 or CREB3L2 (Supplementary Fig. 1c) resulted in decreased *Atf5* expression (Fig. 1b), confirming that these three factors are upstream activators of *Atf5* transcription.

To determine whether *Atf5* expression is modulated by signaling through FGFR, EGFR or RAS, we treated GL261 cells with an inhibitor of FGFR (PD173074)¹⁵, EGFR (CL-387,785)¹⁶, or RAS (manumycin A)¹⁷, and monitored *Atf5* expression by quantitative real-time RT-PCR (qRT-PCR) and immunoblot analysis. All three inhibitors reduced *Atf5* expression at both the mRNA and protein level (Supplementary Fig. 1d,e).

To determine whether downstream signaling pathways of RAS, such as MAPK and phosphoinositide-3-kinase (PI3K), are required for *Atf5* expression, we treated GL261 cells with the RAF kinase inhibitor sorafenib¹⁸, the MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126 (ref. 19), the ERK inhibitor FR180204 (ref. 20), or the PI3K inhibitor LY294002 (ref. 21). All four inhibitors substantially reduced *Atf5* expression, whereas no effect was observed upon treatment with the p38MAPK inhibitor SB203580 (ref. 22) or c-Jun N-terminal kinase (JNK) inhibitor I (ref. 23) relative to the vehicle dimethyl sulfoxide (DMSO) (Fig. 1c).

We next investigated whether CREB3L2 directly regulates *Atf5* expression. Bioinformatic analysis of the *Atf5* promoter revealed a consensus CRE motif at -632 to -639 basepairs upstream of the transcription start-site (Fig. 1d, bottom). Chromatin immunoprecipitation (ChIP) analysis demonstrated that CREB3L2 directly bound to a region of the *Atf5* promoter containing a consensus CRE motif, but not to a region further upstream (Fig. 1d, top). Moreover, binding of CREB3L2 to the *Atf5* promoter was inhibited by sorafenib. To confirm the functional role of CREB3L2 in *Atf5* transcription, we constructed a reporter gene in which ~4 kb of the *Atf5* promoter was fused upstream of the luciferase gene. Figure 1e shows that the wild-type *Atf5* promoter, but not a derivative in which several nucleotides in the CRE motif were mutated (see Fig. 1e, bottom), substantially stimulated luciferase production. Lastly, we found that endogenous *Creb3l2* expression was substantially reduced by treatment of GL261 cells with an siRNA against FRS2 or PAK1, or an inhibitor of MAPK or PI3K (Supplementary Fig. 1f-h). Taken together, these results indicate that FRS2,

PAK1 and CREB3L2 are components of RAS/MAPK- and PI3K-directed pathways that regulate *ATF5* expression.

Next, we performed several experiments to confirm that the ATF5-mediated survival pathway is required for viability of malignant glioma cells. First, shRNA-mediated knockdown of FRS2, PAK1 or CREB3L2 induced apoptosis in GL261 cells, as evidenced by increased caspase 3/7 activity (Fig. 1f). Notably, apoptosis could be rescued by ectopic expression of ATF5. Similarly, the RAF inhibitor sorafenib (Fig. 1g) and inhibitors of FGFR, EGFR, RAS or PI3K (Supplementary Fig. 1i) induced apoptosis in GL261 cells but not in cells ectopically expressing ATF5. By contrast, JNK inhibitor I and SB203580, which did not affect *Atf5* expression (see Fig. 1c), failed to induce apoptosis in GL261 cells (Fig. 1g).

Lastly, we investigated whether the ATF5-mediated survival pathway was required for malignant glioma cell proliferation in a mouse syngenic model. We injected GL261 cells stably expressing ATF5 or empty vector into the flanks of mice, and subsequently administered vehicle or sorafenib by gavage. As expected, control mice injected with GL261 cells developed tumors, whereas tumors were not detected in GL261-injected mice treated with sorafenib (Fig. 1h). Notably, ectopic expression of ATF5 in GL261 cells substantially reduced sensitivity to sorafenib. Taken together, these data indicate that RAS/MAPK- or PI3K-mediated activation of *ATF5* expression is essential for survival of malignant glioma cells both in culture and in mouse xenografts.

ATF5 promotes survival through up-regulation of MCL1

Previous studies have shown that sorafenib can induce apoptosis by decreasing the level of myeloid cell leukemia sequence 1 (MCL1), an anti-apoptotic B-cell leukemia/lymphoma 2 (BCL2) family member²⁴, which we confirmed also occurred in GL261 cells (Fig. 2a). This observation raised the possibility that ATF5 may prevent apoptosis by up-regulating MCL1 expression; we therefore performed a series of experiments to investigate this possibility. Knockdown of ATF5 decreased levels of MCL1, but had no effect on expression of several other anti-apoptotic BCL2 proteins including BCL2, BCL2-like 1 (BCL2L1, also called BCL-XL), and baculoviral IAP repeat-containing 3 (BIRC3, also called cIAP2) (Fig. 2b).

We next sought to determine whether ATF5 regulates *Mcl1* transcription. Knockdown of ATF5 decreased *Mcl1* mRNA levels (Fig. 2c) and, conversely, over-expression of ATF5 increased *Mcl1* mRNA levels (Supplementary Fig. 2). To determine whether ATF5 directly bound to the *Mcl1* promoter, we performed ChIP experiments using a series of primer-pairs that spanned the *Mcl1* promoter. ATF5 binding was enriched at two regions of the *Mcl1* promoter corresponding to -1531/-1358 base pairs (bp) and -853/-718 bp upstream of the transcription start-site (Fig. 2d). Importantly, binding of ATF5 to both *Mcl1* promoter regions was inhibited by sorafenib (Fig. 2d).

We next asked whether MCL1 is required for ATF5-mediated survival by monitoring GL261 cells stably expressing MCL1 for apoptosis following siRNA-mediated knockdown of ATF5. ATF5 knockdown induced apoptosis in control GL261 cells, as evidenced by the production of cleaved caspase 3 (Fig. 2e). Notably, apoptosis was substantially inhibited by

ectopic expression of MCL1. Collectively, these results indicate that MCL1 is a downstream effector of an ATF5-mediated survival pathway (Fig. 2f).

We next asked whether the ATF5-mediated survival pathway is generally active in human cancer cell lines. A search of the Oncomine cancer profiling database^{25,26} revealed that *ATF5* expression is elevated in a wide range of tumors relative to normal tissue (Supplementary Table 2). Moreover, siRNA-mediated knockdown of ATF5 in several diverse human cancer cell lines, U87MG (glioblastoma), DU145 (prostate), UACC62 (melanoma), A549 (lung) and OVCAR3 (ovary), resulted in inhibition of MCL1 expression and induction of apoptosis (Fig. 2g). These results suggest that the ATF5 pathway mediates cell survival in malignant glioma and diverse human cancer cell lines.

ATF5 expression correlates with poor prognosis

Several lines of evidence indicate that the components of the ATF5-mediated survival pathway are highly expressed in malignant glioma. First, as mentioned above, ATF5 is highly expressed in human glioblastoma cells but not normal brain tissues⁵. Second, the *FRS2* gene is amplified in a subset of malignant gliomas²⁷. Finally, previous studies have shown that the activities of PAK1 and ERK correlate with prognosis in glioblastoma^{28,29}. A search of the Oncomine database revealed that, like *ATF5*, *FRS2*, *CREB3L2* and *MCL1* are up-regulated in human glioblastoma compared to normal brain samples (Supplementary Fig. 3a). Moreover, genome-wide analysis of focal copy number in human glioblastoma³⁰ also indicates that components of the ATF5-mediated survival pathway are amplified in the disease (Supplementary Fig. 3b).

To confirm and extend these results, we performed immunohistochemistry on a panel of four normal human brain samples and 38 glioblastomas; representative examples are shown in Fig. 3a, and the results summarized in Supplementary Fig. 3c. Positive staining for phosphorylated ERK (pERK), ATF5, CREB3L2 or MCL1 was found in 50–74% of malignant gliomas and, notably, 42% of malignant gliomas stained positively for all four proteins. By contrast, none of the four proteins were detected by immunohistochemical analysis in normal brain. Statistical analysis revealed a significant correlation in malignant gliomas between pERK and either CREB3L2 or ATF5, and between CREB3L2 and either ATF5 or MCL1 (Supplementary Fig. 3d). By contrast, a significant correlation was not observed between MCL1 and either pERK or ATF5, suggesting that MCL1 expression may be regulated by alternative pathway(s) in malignant glioma. This conclusion is consistent with previous studies demonstrating that MCL1 expression can be regulated by both transcriptional and post-transcriptional mechanisms^{31,32}.

To determine whether there was a correlation between ATF5 expression and prognosis of individuals with glioblastoma, we analyzed the clinical history of 23 individuals with malignant glioma and performed Kaplan-Meier analysis. This analysis revealed that individuals with ATF5-positive glioblastomas had substantially shorter survival times than those with ATF5-negative glioblastomas (Fig. 3b). As expected from previous studies²⁹, pERK showed a similar correlation with clinical outcome. Thus, ATF5 expression is a marker of clinical outcome in individuals with malignant glioma.

Role of the ATF5 pathway in human malignant glioma cells

Malignant glioma is thought to arise from self-renewing progenitors termed glioma stem cells (GSCs)³³, which are highly resistant to chemo- and radio-therapies³⁴. To test whether components of the ATF5-mediated survival pathway are over-expressed in GSCs, we isolated GSCs from either a human malignant glioma primary cell line (GS9-6) or human glioblastoma cell line (D456MG) maintained as a xenograft, and analyzed expression of ATF5-mediated survival pathway components by immunoblot and qRT-PCR analysis. As a control we also monitored the expression of ATF5 pathway components in GS9-6 and D456MG GSCs following induction of differentiation by serum treatment. As expected, serum treatment induced differentiation of GS9-6 GSCs, as evidenced by up-regulation of glial fibrillary acidic protein (GFAP), an astrocytic marker, and down-regulation of nestin, a stem cell marker (Fig. 4a). Upon differentiation, CREB3L2, ATF5 and MCL1 levels decreased, indicating that these proteins are enriched in undifferentiated GS9-6 GSCs. Furthermore, qRT-PCR analysis verified that expression of CREB3L2, ATF5 and MCL1 decreased following differentiation of GS9-6 and D456MG GSCs (Fig. 4b).

To determine whether, as in malignant glioma cells, the ATF5-mediated survival pathway was regulated by MAPK signaling, we treated GS9-6 GSCs with sorafenib, and assessed expression of CREB3L2, ATF5 and MCL1 by immunoblot (Fig. 4c) and qRT-PCR analysis (Fig. 4d). The results show that sorafenib reduced expression of CREB3L2, ATF5 and MCL1 at both the protein and mRNA levels. Furthermore, sorafenib treatment induced apoptosis in GS9-6 GSCs, as evidenced by elevated levels of cleaved caspase 3 (Fig. 4c). Consistent with this result, sorafenib treatment resulted in decreased cell viability of both undifferentiated and differentiated GS9-6 GSCs (Fig. 4e). Thus, the ATF5-mediated survival pathway we identified in mouse malignant glioma is also essential for survival of human malignant glioma cells.

Sorafenib suppresses growth of malignant glioma in mice

To test whether sorafenib could suppress development of brain tumors, we used an established mouse xenograft model of human malignant glioma³⁵. In brief, GSCs were injected intracranially into mice, animals were treated in the presence or absence of sorafenib, and tumor development was monitored by magnetic resonance imaging (MRI). Representative examples are shown in Fig. 5a, and the results quantified in Fig. 5b. All of the mice treated with vehicle harbored a tumor $>5 \text{ mm}^3$ and 50% had a tumor $>25 \text{ mm}^3$. By contrast, only 60% of the mice treated with sorafenib had a tumor $>5 \text{ mm}^3$ and none had a tumor $>25 \text{ mm}^3$. Immunohistochemical staining of tumor sections for cleaved caspase 3 confirmed that sorafenib treatment reduced tumor growth by inducing apoptosis (Fig. 5c,d). Taken together, these data demonstrate that inhibition of MAPK signaling suppresses development of malignant glioma in a mouse model.

Finally, we investigated whether sorafenib could synergize with temozolomide (TMZ), a chemotherapeutic agent used to treat glioblastomas³⁶, to inhibit tumor cell growth. We found that sorafenib and TMZ synergistically decreased viability of U87MG human glioblastoma cells (Fig. 6a), which express high levels of *ATF5* and *CREB3L2* (Supplementary Fig. 4a), but not SF295 human glioblastoma cells (Supplementary Fig. 4b),

which express low levels of *ATF5* and *CREB3L2* (Supplementary Fig. 4a). We also observed a synergistic effect on tumor growth in U87MG mouse xenografts (Fig. 6b). Taken together, these results indicate that sorafenib can sensitize glioblastoma cells to TMZ, and further suggest that such sensitization selectively occurs in cells expressing high levels of *ATF5*.

DISCUSSION

ATF5 is expressed at high levels in malignant glioma but not in mature neurons or astrocytes⁶. Moreover, interference with *ATF5* function results in glioma cell death in primary tumors without affecting normal cells surrounding the tumor⁶. These findings suggest that *ATF5* is an attractive target for the development of therapeutics for malignant glioma⁴. However, *ATF5* is a transcription factor, a class of molecules for which the development of small molecule drugs has proven challenging³⁷. An alternative strategy to targeting *ATF5* directly is to interfere with upstream regulators of *ATF5* expression or downstream effectors through which *ATF5* promotes survival.

In this report, we have described a novel negative-selection strategy using genome-wide RNAi screening to elucidate RAS/MAPK- and PI3K-directed signaling pathways by which *ATF5* is expressed and promotes survival of malignant glioma cells. The genome-wide RNAi screening strategy we have developed can be generally applied to identify other survival pathways in cancer cells. Our results enable us to propose a model for an essential survival pathway in malignant glioma and other solid tumors (Fig. 2f). An FRS2/PAK1-activated RAS/MAPK signaling cascade up-regulates *CREB3L2*, which directly binds to the *ATF5* promoter resulting in *ATF5* transcription. FRS2 may also activate *ATF5* transcription through PI3K signaling. *ATF5* then stimulates *MCL1* transcription by binding to its promoter, resulting in increased levels of the anti-apoptotic protein *MCL1*, which promotes cell survival. Our results do not rule out the possibility that other *ATF5* targets, which remain to be identified, may also contribute to the inhibition of apoptosis.

We have shown that pharmacological inhibition of this pathway substantially decreases *ATF5* levels and blocks proliferation of malignant glioma cells both in cell culture and in mouse tumor models. Our experiments were carried out using the well-characterized RAF inhibitor sorafenib at concentrations in cultured cells and at doses in mice^{38–40} that approximate the levels of sorafenib achieved in subjects treated with the drug^{41–44}. Moreover, we have found that in the presence of TMZ, the drug most commonly used to treat malignant glioma, the concentration of sorafenib required for growth inhibition is dramatically reduced. Thus, when combined with TMZ, the sorafenib concentration obtainable in subjects may be well above that required for an effective response. Finally, although our sorafenib results clearly demonstrate that the pro-survival pathway we have identified can be pharmacologically inhibited, it is likely that more recently developed RAF inhibitors⁴⁵, and inhibitors of other components of this *ATF5*-mediated survival pathway, such as MEK, may be even more efficacious.

METHODS

RNAi

For pATF5-DTR, we amplified 4117 bp of the mouse *Atf5* promoter from a BAC clone and cloned it into pEF4/Myc-His B (Invitrogen), then amplified the human DTR gene from mCD11C-DTR-EGFP46 and cloned it downstream of the *Atf5* promoter. For pCMV-ATF5, we amplified ATF5 cDNA from pCMV-SPORT6-ATF5 (Open Biosystems) and cloned it into p3XFlag-myc-CMVTM-26 (Sigma). We transduced GL261 cells stably expressing pATF5-DTR and pCMV-ATF5 with retroviral pools of a mouse shRNA^{mir} library (Open Biosystems) as described⁴⁷. We incubated cells with 100 pM DT for 7 d, and cultured surviving cells in media without DT for 2 weeks. To validate candidates, we transiently transfected GL261 cells with an individual shRNA, and assessed expression of endogenous *Atf5* by RT-PCR (using primers listed in Supplementary Table 3) quantified using Image J software. For RNAi, we transiently transfected GL261 cells (5×10^5) with an siRNA or shRNA (Supplementary Table 3) using Effectene (QIAGEN).

Quantitative RT-PCR

Quantitative RT-PCR was performed as previously described⁴⁷ using primers listed in Supplementary Table 3.

ChIP

ChIP assays were performed as previously described⁴⁸ using antibodies listed in Supplementary Table 3. Immunoprecipitated DNA was amplified by real-time PCR (primers listed in Supplementary Table 3).

Luciferase reporter assay

We cloned the mouse *Atf5* promoter into pGL4.14 (*luc2*/Hygro; Promega), and mutated the CRE element into a Not I site. We co-transfected this plasmid and pGL4.73 (hRluc/SV40; Promega) into GL261 cells and assessed luciferase activity 48 h later using the Dual-Luciferase Reporter Assay System (Promega). Relative luciferase activity was calculated and normalized to empty vector.

Apoptosis assays

We measured apoptosis using a Caspase-Glo[®] 3/7 Assay (Promega). To eliminate background caspase activity, caspase 3/7 activity was normalized to cell number (obtained from an MTT assay), and then to the activity obtained with the control shRNA.

Preparation of GSCs

For GS9-6, a freshly-resected tumor, never treated with radio- or chemotherapy, was dispersed with trypsin and placed into neurosphere culture in DMEM/F12 medium supplemented with B27 (Invitrogen), 20 ng ml⁻¹ fibroblast growth factor (PeproTech) and 20 ng ml⁻¹ epidermal growth factor (PeproTech). For passaging, we dispersed neurospheres using a basic solution⁴⁹ and maintained them in the media described above. D456MG GSCs were prepared as previously described³⁴.

Mouse tumorigenesis assays

For the syngenic model, we injected 1×10^6 GL261 cells subcutaneously into the flank of C57/BL6 mice (Taconic), aged 8 weeks. Tumor volume was calculated $[(\text{length} \times \text{width}^2) \times (\pi/6)]$. We fed mice daily with sorafenib (60 mg kg^{-1}) or vehicle (cremophor:ethanol:water 12.5%:12.5%:75%) through gavage starting at 4 d. Mice were sacrificed 31 d after injection. For the xenograft model, we implanted 5×10^5 GS9-6 cells stereotaxically in the right frontal lobe [from bregma, anteroposterior, 2 mm; mediolateral, 2 mm; ventral (from dura), 2 mm] of NIH-bg-nu-xidBR mice (Charles River Laboratories) as described³⁵. We administered sorafenib (100 mg kg^{-1}) or vehicle daily through gavage starting at 7 d. Tumor growth was monitored at the UMMS Image Core of Advanced MRI using Philips DICOM Viewer R2.4, and tumor volume was calculated (length \times width \times depth). After 81 d mice were imaged and sacrificed, and their brains sectioned and fixed in formalin. We performed all animal experiments in accordance with the Institutional Animal Care and Use Committee guidelines.

Temozolomide experiments

We treated U87MG or SF295 cells with sorafenib, TMZ (Sigma) or both for 4 d, and monitored cell viability by MTT assay. For the xenografts, we injected 5×10^6 U87MG cells subcutaneously into the flank of nude mice (Taconic), aged 6–8 weeks. Starting at 15 d, we fed mice daily with sorafenib (20 mg kg^{-1}), TMZ (7.5 mg kg^{-1}) or a combination of both through gavage, then treated with sorafenib for another 10 d. Mice were sacrificed 30 d after injection. Tumor dimensions were measured every 3 d and tumor volume was calculated.

Statistical analyses

We performed all analyses in R 2.9.050. We performed Welch two sample t-test⁵¹ on log-transformed qPCR data (Figs. 1b,c,e; 2a,c; 4d) and log-transformed relative caspase activity data (Fig. 1f,g). We performed repeated measure analysis of variance on log-transformed tumor volume (Figs. 1h, 6b). In addition, we performed a list of pre-determined contrasts to test whether sorafenib treatment decreases tumor volume in the absence or presence of ATF5, and whether combined sorafenib and TMZ treatment decreases tumor volume significantly compared with sorafenib or TMZ treatment alone. We applied ANOVA to the rank-transformed cell viability data to test the effect of serum, sorafenib and the interaction of serum and sorafenib (Fig. 4e) and of TMZ, sorafenib and the interaction of TMZ and sorafenib (Fig. 6a). A linear mixed-effects model was fit to the log-transformed tumor volumes (Fig. 5b) or number of apoptotic cells (Fig. 5d) with treatment as a fixed effect and experiment day as random effect to determine whether the tumor size differs between treatments using R package nlme_3.1–90.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Y. Gillespie (University of Alabama at Birmingham), D. Bigner (Duke University) and R. Lang (University of Cincinnati) for reagents; the University of Massachusetts Medical School RNAi Core Facility for

providing shRNAs; the UMMS Department of Pathology for providing human tissue sections, and the UMMS DERC Morphology core for performing the immunohistochemistry; K. Rock for suggesting the diphtheria toxin strategy; Y. Sun for critical advice on MRI; C. Gilbert for maintaining GS9-6 cells; S. Griggs for technical support; and S. Evans for editorial assistance. This work is supported by US National Institutes of Health grant RO1CA115817 to M.R.G. M.R.G is an investigator of the Howard Hughes Medical Institute.

References

1. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000; 100:57–70. [PubMed: 10647931]
2. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell*. 2009; 136:823–837. [PubMed: 19269363]
3. Persengiev SP, Green MR. The role of ATF/CREB family members in cell growth, survival and apoptosis. *Apoptosis*. 2003; 8:225–228. [PubMed: 12766482]
4. Greene LA, Lee HY, Angelastro JM. The transcription factor ATF5: role in neurodevelopment and neural tumors. *J. Neurochem*. 2009; 108:11–22. [PubMed: 19046351]
5. Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. *Int. J. Cancer*. 2007; 120:1883–1890. [PubMed: 17266024]
6. Angelastro JM, et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. *Oncogene*. 2006; 25:907–916. [PubMed: 16170340]
7. Persengiev SP, Devireddy LR, Green MR. Inhibition of apoptosis by ATFx: a novel role for a member of the ATF/CREB family of mammalian bZIP transcription factors. *Genes Dev*. 2002; 16:1806–1814. [PubMed: 12130540]
8. Collier RJ. Diphtheria toxin: mode of action and structure. *Bacteriol. Rev*. 1975; 39:54–85. [PubMed: 164179]
9. Silva JM, et al. Second-generation shRNA libraries covering the mouse and human genomes. *Nat. Genet*. 2005; 37:1281–1288. [PubMed: 16200065]
10. Sato T, Gotoh N. The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment. *Expert. Opin. Ther. Targets*. 2009; 13:689–700.
11. da Fonseca CO, et al. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. *Surg. Neurol*. 2006; 65(Suppl 1):S1:2–S1:8. discussion S1:8-1:9. [PubMed: 16427438]
12. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. *Nat. Rev. Cancer*. 2006; 6:459–471. [PubMed: 16723992]
13. Kondo S, et al. BBF2H7, a novel transmembrane bZIP transcription factor, is a new type of endoplasmic reticulum stress transducer. *Mol. Cell. Biol*. 2007; 27:1716–1729. [PubMed: 17178827]
14. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. *Neuron*. 2002; 35:605–623. [PubMed: 12194863]
15. Mohammadi M, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. *EMBO J*. 1998; 17:5896–5904. [PubMed: 9774334]
16. Discafani CM, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazoliny]-2-butynamide (CL-387,785). *Biochem. Pharmacol*. 1999; 57:917–925. [PubMed: 10086326]
17. Hara M, et al. Identification of Ras farnesyltransferase inhibitors by microbial screening. *Proc. Natl. Acad. Sci. U. S. A*. 1993; 90:2281–2285. [PubMed: 8460134]
18. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. *Curr. Pharm. Des*. 2002; 8:2255–2257. [PubMed: 12369853]
19. Favata MF, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J. Biol. Chem*. 1998; 273:18623–18632. [PubMed: 9660836]
20. Ohori M, et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. *Biochem. Biophys. Res. Commun*. 2005; 336:357–363. [PubMed: 16139248]

21. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *J. Biol. Chem.* 1994; 269:5241–5248. [PubMed: 8106507]
22. Cuenda A, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. *FEBS Lett.* 1995; 364:229–233. [PubMed: 7750577]
23. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. *Diabetes.* 2001; 50:77–82. [PubMed: 11147798]
24. Yu C, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. *Oncogene.* 2005; 24:6861–6869. [PubMed: 16007148]
25. Rhodes DR, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia.* 2007; 9:166–180. [PubMed: 17356713]
26. Sun L, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. *Cancer Cell.* 2006; 9:287–300. [PubMed: 16616334]
27. Fischer U, et al. A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma. *Mol Cancer Res.* 2008; 6:576–584. [PubMed: 18403636]
28. Aoki H, et al. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. *Clin. Cancer Res.* 2007; 13:6603–6609. [PubMed: 18006760]
29. Pelloski CE, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. *Clin. Cancer Res.* 2006; 12:3935–3941. [PubMed: 16818690]
30. Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science.* 2008; 321:1807–1812. [PubMed: 18772396]
31. Rahmani M, et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. *Mol. Cell. Biol.* 2007; 27:5499–5513. [PubMed: 17548474]
32. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. *J. Biol. Chem.* 2005; 280:35217–35227. [PubMed: 16109713]
33. Alcantara Llaguno S, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. *Cancer Cell.* 2009; 15:45–56. [PubMed: 19111880]
34. Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature.* 2006; 444:756–760. [PubMed: 17051156]
35. Li L, et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. *Neuro. Oncol.* 2009; 11:9–21. [PubMed: 18812521]
36. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. *Cancer Chemother. Pharmacol.* 2009; 64:647–655. [PubMed: 19543728]
37. Weiss WA, Taylor SS, Shokat KM. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. *Nat. Chem. Biol.* 2007; 3:739–744. [PubMed: 18007642]
38. Sparidans RW, et al. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2009; 877:269–276.
39. Lagas JS, et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. *Mol. Cancer Ther.* 2010; 9:319–326. [PubMed: 20103600]
40. Hu S, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. *Clin. Cancer Res.* 2009; 15:6062–6069. [PubMed: 19773380]
41. Awada A, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. *Br. J. Cancer.* 2005; 92:1855–1861. [PubMed: 15870716]
42. Strumberg D, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. *J. Clin. Oncol.* 2005; 23:965–972. [PubMed: 15613696]
43. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. *Clin. Cancer Res.* 2005; 11:5472–5480. [PubMed: 16061863]

44. Richly H, et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. *Ann. Oncol.* 2006; 17:866–873. [PubMed: 16500908]
45. McCubrey JA, et al. Emerging Raf inhibitors. *Expert. Opin. Emerg. Drugs.* 2009; 14:633–648. [PubMed: 19715444]
46. Jung S, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. *Immunity.* 2002; 17:211–220. [PubMed: 12196292]
47. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. An elaborate pathway required for Ras-mediated epigenetic silencing. *Nature.* 2007; 449:1073–1077. [PubMed: 17960246]
48. Sheng Z, Wang SZ, Green MR. Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R. *EMBO J.* 2009; 28:866–876. [PubMed: 19229297]
49. Sen A, Kallos MS, Behie LA. New tissue dissociation protocol for scaled-up production of neural stem cells in suspension bioreactors. *Tissue Eng.* 2004; 10:904–913. [PubMed: 15265308]
50. Ihaka R, Gentleman R. A language for data analysis and graphics. *J. Comput. Graph. Stat.* 1996; 5:299–314.
51. Ruxton GD. The unequal variance t-test is an underused alternative to Student's t-test and the Mann-Whitney U test. *Behavioral Ecology.* 2006; 17:688–690.





Figure 1. A genome-wide RNAi screen reveals a signaling pathway required for ATF5 expression. (a) Schematic summary of the genome-wide RNAi screen. (b) qRT-PCR analysis of endogenous *Atf5* expression in GL261 cells transiently transfected with a luciferase (Luc), FRS2, PAK1 or CREB3L2 siRNA. (c) qRT-PCR analysis of endogenous *Atf5* expression in GL261 cells treated with sorafenib (10 μ M), U0126, FR180204, LY294002, JNK inhibitor I, SB203580 or, as a control, DMSO. (d) ChIP analysis monitoring binding of CREB3L2 to two regions of the *Atf5* promoter in GL261 cells treated with or without sorafenib (10 μ M).

A consensus CRE motif is present at –632 to –639 bp upstream of the transcription start-site (bottom). Enrichment of CREB3L2 is expressed relative to a no antibody control. **(e)** Luciferase reporter assay in GL261 cells transiently transfected with an *Atf5* promoter reporter construct carrying a wild-type (WT) or mutant (Mut) CRE. **(f)** Caspase 3/7 activity assay in GL261 cells stably expressing Flag-ATF5 or, as a control, Flag and transiently transfected with a non-silencing (NS), FRS2, PAK1 or CREB3L2 shRNA. **(g)** Caspase 3/7 activity assay in GL261 cells expressing Flag or Flag-ATF5 and treated with either DMSO, sorafenib (20 μ M), JNK inhibitor I or SB203580. **(h)** Mouse tumorigenesis assays. Sorafenib treatment decreased tumor volume significantly in the absence of ATF5 ($P = 0.0045$) but not in the presence of ATF5 ($P = 0.62$). All error bars shown, \pm s.d.; * $P < 0.05$; ** $P > 0.05$.

**Figure 2.**

ATF5 promotes survival through up-regulation of MCL1. (a) qRT-PCR analysis of *Mcl1* expression in GL261 cells treated with DMSO, sorafenib (10 μ M), U0126, FR180204, JNK inhibitor I or SB203580. (b) Immunoblot analysis monitoring ATF5, MCL1, BCL2, BCL-XL or cIAP2 levels in GL261 cells transiently transfected with a Luc or ATF5 siRNA. β -actin (ACTB) was monitored as a loading control. (c) qRT-PCR analysis of *Mcl1* expression in GL261 cells transiently transfected with a Luc or ATF5 siRNA. (d) ChIP analysis monitoring binding of ATF5 to three regions of the *Mcl1* promoter, as indicated, in the presence or absence of sorafenib (10 μ M). (e) Immunoblot analysis monitoring cleaved caspase 3 (c-CASP3) levels in GL261 cells stably expressing either Flag or Flag-MCL1, and transiently transfected with a Luc or ATF5 siRNA. (f) A model depicting the ATF5-mediated survival pathway in solid tumors. (g) Immunoblot analysis monitoring ATF5, MCL1 and c-CASP3 levels in U87MG, DU145, UACC62, A549 and OVCAR3 cells treated with a Luc or ATF5 siRNA. All error bars shown, \pm s.d.; * P < 0.05; ** P > 0.05.




Figure 3.

ATF5 expression correlates with poor prognosis in human malignant glioma. **(a)** Immunohistochemical analysis of phosphorylated ERK (pERK), CREB3L2, ATF5, and MCL1 in brain tissue sections from a normal individual and glioblastoma subject. Samples were also stained with hematoxylin and eosin (H&E) (left). **(b)** Kaplan-Meier analysis assessing the correlation between survival of 23 individuals with malignant glioma and the expression of ATF5 (left) or pERK (right). The *P*-value of both ATF5 and pERK expression


in subject survival was 0.03. “Month” refers to the time of death after the malignant glioma was first diagnosed.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Figure 4.**

The ATF5-mediated survival pathway is essential for viability of human malignant glioma cells. **(a)** Immunoblot analysis of pERK, ERK, CREB3L2, ATF5, MCL1, GFAP and nestin (NES) in GS9-6 GSCs treated in the presence or absence of serum. **(b)** qRT-PCR analysis monitoring *CREB3L2*, *ATF5*, *MCL1*, *CD133*, *NES* and *GFAP* in D456MG and GS9-6 GSCs treated in the presence relative to absence of serum. **(c)** Immunoblot analysis of CREB3L2, ATF5, MCL1 and c-CASP3 in GS9-6 GSCs treated in the absence or presence of 40 μM sorafenib. **(d)** qRT-PCR analysis of *CREB3L2*, *ATF5* and *MCL1* in GS9-6 GSCs treated in the absence or presence of 40 μM sorafenib. **(e)** Cell viability, monitored by MTT assay, of GS9-6 GSCs incubated with or without serum, and then treated with sorafenib for 96 h. Cell viability was significantly affected by sorafenib treatment ($P = 3.53e-07$). All error bars shown, \pm s.d.; * $P < 0.05$; ** $P > 0.05$.




Figure 5.

Inhibition of MAPK signaling suppresses development of malignant glioma in mouse xenografts. **(a)** Mouse xenograft experiments. Tumor formation was monitored by MRI (left); the position of the tumor is indicated by the arrow. Brain sections were stained with H&E (middle) or an antibody against GFAP (right) to verify the glial origin of the tumor. Expression of CREB3L2, ATF5 and MCL1 in these sections is shown in Supplementary Fig. 5. **(b)** Quantification of tumor size based on MRI images. Sorafenib significantly inhibited tumor formation ($P = 0.0344$). **(c)** c-CASP3 staining in brain sections from vehicle- or sorafenib-treated mice; arrows indicate c-CASP3-positive (apoptotic) cells. **(d)** c-

CASP-3-positive cells were counted in three different fields under the microscope, and the average value is shown. All error bars shown, \pm s.d.; * $P < 0.05$; ** $P > 0.05$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 6.

Sorafenib synergizes with temozolomide to inhibit tumor cell growth. (a) U87MG cells were treated with combinations of sorafenib and TMZ, and cell viability was measured using an MTT assay. The combination of sorafenib and TMZ significantly decreased cell viability ($P = 1.468e-05$). (b) Mouse xenograft experiments. The combination of sorafenib and TMZ treatment significantly decreased tumor volume compared to sorafenib ($P = 4.4e-05$) or TMZ ($P = 5.6e-06$) alone. All error bars shown, \pm s.d.